BUSINESS
Dishman Pharma & Chemicals has recently reached commercialisation stage for a $50 million deal it had signed with EU multinational to manufacture cardiovascular intermediates.
Dishman Pharma & Chemicals, a medium-sized company that has been witnessing revenue decline over the last few quarters, stands to benefit from a strong deal pipeline and new facilities getting operational, which will lead to better revenues next fiscal.
The company has recently reached commercialisation stage for a $50 million deal it had signed with EU multinational to manufacture cardiovascular intermediates. This deal comes under the CRAMS segment, which contributes three-fourths of its consolidated revenues but has not been doing well of late due to a slowdown in order inflows. It also has a strong potential deal pipeline but hasn’t reached commercial execution stage.
Further, the company has signed an agreement for another CVS product with a US-based MNC and has entered into master supply agreement with another US customer. It is in advanced talks with other MNCS as well.
Dishman’s operating margins had fallen drastically by over 500 bps last quarter to 17.4% on account of lower contribution from the higher-margin CRAMS segment. However, analysts believe the worst is over and the company would slowly show recovery from the fourth quarter.
“The margins are expected to improve, driven by the strong growth and the commercialisation of the high-margin HIPO facility. However, the contract research business would remain under pressure as research activity has not picked up in regulated markets (the US and EU), post-recession,” Sriram Rathi and Sanjeev Chiniwar, analysts at Anand Rathi Financial Services, wrote in a company update dated December 6.
The company is also expected to benefit from commercialisation of its new plants at Bawla and China. Its new high-potency (HIPO) plant (unit 9) at Bawla for the manufacturing anticancer products is expected to become operational by next month and its another plant (unit 10) for manufacturing disinfectants would also commence operations by early FY12. The company has converted its SEZ facility in China for CRAMS manufacturing also. These facilities are likely to aid revenues in FY12.
The stock of Dishman Pharma & Chemicals, which had hit a yearly low of Rs128 on December 9, gained 3.25% on Tuesday to close at Rs154.10. The stock has been on an uptrend over the last few days on improving revenue visibility and most analysts remain positive on it from a long-term perspective.
What led to stampede at New Delhi Railway Station that killed 18 people? 10 points
King Kong: This 6-Foot-8 buffalo named the world’s tallest by Guinness World Records
Shakira’s metallic wolf gown took 600 hours to create, designed by THIS Indian couturier
84 year marriage, 13 kids, 100 grandkids, viral couple sets record
Harshvardhan Rane, Mawra Hocane react to Amitabh Bachchan's shout out to Sanam Teri Kasam re-release
Chhaava box office collection day 2: Vicky Kaushal, Akshaye Khanna film mints Rs 67 crore
15 injured in stampede at New Delhi Railway Station, probe on
Amitabh Bachchan was 'mind-blown' in a Bangkok strip club, reveals...: 'He was wearing...'
Watch: Gautam Adani and his wife offered 'chadar' at Ajmer Sharif Dargah
European man shares 10 lessons that shattered his western mindset after moving to India
'India needs strong production base, not empty words': LoP Rahul Gandhi's veiled dig at centre
Ranveer Allahbadia says he’s getting death threats from..., promises he won’t...
Bad news for Rohit Sharma ahead of Champions Trophy 2025, BCCI to take huge step on India captain
Mukesh Ambani's Reliance Industries buys new company for Rs 6.73 crore, it is called...
Who was Lavoo Mamledar, former MLA who died after altercation with...in...
World's largest gold deposit worth over Rs 7 lakh crore found in China, hidden beneath....
Video Viral: Monalisa Bhosle, Mahakumbh sensation, takes first-ever flight to Kozhikode
Who Owns Burj Khalifa? Know the SURPRISING owner of the world's tallest building
Legendary Bengali singer-songwriter Pratul Mukhopadhyay passes away at 82
Whale swallows, then spits out kayaker as moment is captured on camera; WATCH viral video
'I do not regret being part of it': Raghu Ram opens up on India's Got Latent controversy
Meet influencer Ashley Clair who claims Tesla CEO Elon Musk is the father of her child
After Virat Kohli, Yuvraj Singh cuts ties with Ranveer Allahabadia – Here's what happened!
NASA’s curiosity Rover captures stunning twilight clouds on Mars, leaves internet in awe
Who is Ashley St. Clair? Author claiming she secretly gave birth to Elon Musk's child
Google secures Mumbai's BKC offices, renews lease with staggering monthly rent of over Rs.....
Meet man, who sold previous company for Rs 1 lakh crore, he is...
American whiskey Bourbon set to take over Indian market, here's how
Ten devotees from Chhattisgarh killed as car collides with bus enroute to Maha Kumbh
What happens after UPSC? Civil servants share about life at LBSNAA
Mukesh Ambani, sons Akash and Anant take holy dip at Mahakumbh, woman shares video; watch here
'What Akshay Kumar does is..': Ahmed Khan reveals superstar uses teleprompter for…, defends his…
Ameesha Patel shares 'fraudulent promise' video of Gadar 2 because Anil Sharma...: 'How will you...'
Maha Kumbh fame IIT Baba aka Abhay Singh's 10th, 12th marksheet goes viral
After Cristiano Ronaldo, Lionel Messi’s teammate Federico Redondo takes dig at PSG, claims...
Who is Abhinav Chandrachud? Lawyer representing YouTuber Ranveer Allahbadia, he is son of famous...
India's Got Latent controversy: YouTuber Apoorva Makhija kicked out from IIFA? Here's what we know
Former WWE wrestler gives BIG warning to Ranveer Allahbadia, says, 'people like him have...'
Ukraine's Zelenskyy makes BIG claim, says Donald Trump can push Putin to...
Anti-Valentine’s week: From Breakup Day to Slap Day, 7 days explained
Saturday bank holiday: Are banks open or closed on February 15? Check here
Meet Fearless Nadiya, first female Bollywood action star, she was from...